Dishman Carbogen, Client to Invest CHF 25M to Expand Swiss Sites
ECONOMY & POLICY

Dishman Carbogen, Client to Invest CHF 25M to Expand Swiss Sites

The Company’s subsidiary, CARBOGEN AMCIS AG, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, is pleased to announce a strategic co-investment of more than CHF 25 million with a long-standing Japanese customer to expand manufacturing capabilities at its sites in Aarau and Neuland, Switzerland.

The investment will support the production of a drug linker for a commercial antibody-drug conjugate (ADC), enabling CARBOGEN AMCIS to meet rising global demand. As part of the agreement, both facilities will see significant equipment and infrastructure enhancements, including:

  • Aarau site: installation of 850-litre reactors and 0.4 m² agitated filter dryers with supporting equipment. Completion is expected by Q1 2027.
  • Neuland site: installation of 850-litre reactors and 0.4 m² agitated filter dryers with auxiliary systems. Completion is anticipated by Q3 2027.

This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021 to develop a site extension at the Bubendorf site in Switzerland, reinforcing the strength of the relationship and their shared commitment to long-term growth.

“This expansion demonstrates our ability to scale alongside our customers, responding to the increasing demand for complex and high-value compounds such as ADC drug linkers,” said Stephan Fritschi, CEO at CARBOGEN AMCIS. “We’re proud to continue building on our strong trust and technical collaboration foundation.”

CARBOGEN AMCIS is recognised for its robust capabilities in handling highly potent compounds, offering end-to-end support from process development to commercial supply. The new investments will further strengthen the company’s infrastructure to deliver high-quality manufacturing services in line with cGMP and global regulatory expectations.

“By investing in both Aarau and Neuland, we’re ensuring that our infrastructure keeps pace with our customers’ ambitions,” said Carl Baker, Vice President Business Unit Drug Substance. “These upgrades will allow us to seamlessly manage increased volumes while maintaining the operational excellence and containment controls required for highly potent APIs and advanced therapies.”

With facilities across Switzerland, France, the UK, the Netherlands, and China, CARBOGEN AMCIS continues to expand its global footprint while delivering flexible, integrated CDMO solutions to pharmaceutical and biopharmaceutical innovators worldwide.

The Company’s subsidiary, CARBOGEN AMCIS AG, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, is pleased to announce a strategic co-investment of more than CHF 25 million with a long-standing Japanese customer to expand manufacturing capabilities at its sites in Aarau and Neuland, Switzerland.The investment will support the production of a drug linker for a commercial antibody-drug conjugate (ADC), enabling CARBOGEN AMCIS to meet rising global demand. As part of the agreement, both facilities will see significant equipment and infrastructure enhancements, including:Aarau site: installation of 850-litre reactors and 0.4 m² agitated filter dryers with supporting equipment. Completion is expected by Q1 2027.Neuland site: installation of 850-litre reactors and 0.4 m² agitated filter dryers with auxiliary systems. Completion is anticipated by Q3 2027.This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021 to develop a site extension at the Bubendorf site in Switzerland, reinforcing the strength of the relationship and their shared commitment to long-term growth.“This expansion demonstrates our ability to scale alongside our customers, responding to the increasing demand for complex and high-value compounds such as ADC drug linkers,” said Stephan Fritschi, CEO at CARBOGEN AMCIS. “We’re proud to continue building on our strong trust and technical collaboration foundation.”CARBOGEN AMCIS is recognised for its robust capabilities in handling highly potent compounds, offering end-to-end support from process development to commercial supply. The new investments will further strengthen the company’s infrastructure to deliver high-quality manufacturing services in line with cGMP and global regulatory expectations.“By investing in both Aarau and Neuland, we’re ensuring that our infrastructure keeps pace with our customers’ ambitions,” said Carl Baker, Vice President Business Unit Drug Substance. “These upgrades will allow us to seamlessly manage increased volumes while maintaining the operational excellence and containment controls required for highly potent APIs and advanced therapies.”With facilities across Switzerland, France, the UK, the Netherlands, and China, CARBOGEN AMCIS continues to expand its global footprint while delivering flexible, integrated CDMO solutions to pharmaceutical and biopharmaceutical innovators worldwide.

Next Story
Infrastructure Energy

SJVN Green Adds 100 MW Solar Capacity in Bikaner

SJVN Green Energy Ltd (SGEL), a wholly owned subsidiary of SJVN, has commenced commercial operations of an additional 100.02 MW from its 1,000 MW solar power project in Bikaner, Rajasthan. With this, the total commercially operational capacity at the site now stands at 501.02 MW.In a regulatory filing on Monday, SJVN confirmed that the newly added capacity became operational on 30 June 2025. The balance capacity is expected to be commissioned in the near future, progressively bringing the entire 1,000 MW project online.The Bikaner solar project is one of SGEL’s key renewable energy initiativ..

Next Story
Infrastructure Urban

India, RAK Mull Long Term Deal For Limestone And Green Steel

Union Steel Minister H D Kumaraswamy met Ras Al Khaimah (RAK) ruler Saud Bin Saqr Al Qasimi in Dubai to discuss securing long term access to low silica limestone from the UAE and collaborating on green steel production. The talks coincided with the Minister’s inauguration of new overseas offices for state owned engineering firm MECON and miner NMDC.Both sides examined opportunities in green hydrogen, value added steel exports from India, and setting up calcined lime plants in RAK that would use the emirate’s limestone and natural gas. Kumaraswamy invited RAK to join Indian ..

Next Story
Real Estate

Mahindra Lifespace Buys 9 Acre Plot in Bengaluru for Rs 2 Bn

Mahindra Lifespace Developers Ltd has purchased Shreyas Stones Pvt Ltd, which owns an 8.79 acre parcel at Navaratna Agrahara in North Bengaluru, for approximately Rs 2.0 billion. The share purchase agreement transfers one hundred per cent of SSPL’s equity—10,000 shares of Rs 10 each—to Mahindra Lifespace.The site will be integrated with an adjacent Mahindra holding, creating a unified premium housing scheme with a projected gross development value of about Rs 21.0 billion. On its own, the newly acquired plot is expected to generate roughly Rs 11.0 billion in sales..

Advertisement

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

Advertisement

Talk to us?